David Rosenthal, MD
Associate Professor of Medicine (General Medicine)Cards
About
Research
Publications
2026
The differential effects of social support on quality of life in head and neck cancer patients in the United States and China
Ratcliff C, Ahn A, Custodio A, Garcia M, Meng Z, Rosenthal D, Shen Y, Chambers M, Hu C, Cohen L. The differential effects of social support on quality of life in head and neck cancer patients in the United States and China. European Journal Of Oncology Nursing 2026, 81: 103156. PMID: 41723882, DOI: 10.1016/j.ejon.2026.103156.Peer-Reviewed Original ResearchFACT-GSocial supportMedical Outcomes Study Social Support ScaleFunctional Assessment of Cancer Therapy-General (FACT-GSubscale scoresImpact of social supportFunctional assessmentEffect of social supportAssociated with QoLSocial Support ScaleCancer patientsQuality of lifeUnited StatesHead and neck cancer patientsEmotional/informational supportMOS-SSSCulturally specific factorsSupport ScaleTangible supportCancer populationNeck cancer patientsSecondary analysisQoLTotal scoreSS total scoreTreatment Interruption and Outcomes in Head and Neck Cancer
Gharzai L, Morris E, Schipper M, Kidwell K, Nguyen-Tân P, Rosenthal D, Gillison M, Jordan R, Garden A, Koyfman S, Caudell J, Blakaj D, Dunlap N, Krempl G, Longo J, Jones C, Gensheimer M, Galloway T, DeMora L, Le Q, Shah J, Suresh K, Mierzwa M. Treatment Interruption and Outcomes in Head and Neck Cancer. JAMA Otolaryngology - Head & Neck Surgery 2026, 152: 144-153. PMID: 41343184, PMCID: PMC12679426, DOI: 10.1001/jamaoto.2025.4203.Peer-Reviewed Original ResearchHead and neck squamous cell carcinomaLocoregional failureRT interruptionOverall survivalP16 statusTreatment interruptionHazard ratioAssociated with poor oncological outcomesNeck squamous cell carcinomaHead and neck cancerP16-negative cancersHigher-stage diseaseTreated with RTPoor oncological outcomesSquamous cell carcinomaCox proportional hazards modelsAssociated with hazard ratiosRandomized clinical trialsSecondary analysisProportional hazards modelNon-T4Oncological outcomesTumor characteristicsRetrospective reviewCell carcinoma
2025
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Frank S, Busse P, Lee J, Rosenthal D, Hernandez M, Swanson D, Garden A, Gunn G, Patel S, Snider J, J D, Molitoris J, Lee N, Parvathaneni U, McDonald M, Kalman N, Lin A, Mohammed N, Henson C, Hyde C, Bajaj G, Katz S, Dagan R, Morrison W, Reddy J, Fuller C, Shah S, Phan J, Chronowski G, Mayo L, Sturgis E, Ferrarotto R, Zhu X, Zhang X, Wang L, Hutcheson K, El-Naggar A, Moreno A, Lee A, Spiotto M, Gross N, Lai S, Liao J, Paly J, Liao Z, Foote R, Consortium T, Bates J, Chambers M, Chun S, Kaiser A, Lester S, Lukens J, McGee L, Neben-Wittich M, Nguyen Q, Routman D, Schlembach P, Skinner H, Soike M, Rwigema J, Wiederhold L, Blanchard P, Choi I, Koong A, Langendijk H, Mohan R, Carlson B, Mapps A, Sarmiento J, Teferra M, Bosch W, Followill D, Taylor P, Fuentes S, Ning M, Toumazis I, Wogan C, De Gracia B, Fink K, Grippin A, Ma J, Pettersen E, Sareyeldin R, Cronin C, Muise S, Johnson M, Pyfferoen K, Tranby B, Leonard J, Watkin S, Eggleston C, Barrow B, Wolcott J, Antonio J, Brand J, Cleverdon A, Drake M, Peters E, Small C, Clark K, Holder R. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet 2025, 407: 174-184. PMID: 41391462, PMCID: PMC12812248, DOI: 10.1016/s0140-6736(25)01962-2.Peer-Reviewed Original ResearchIntensity-modulated radiation therapy groupIMPT groupIntensity-modulated proton therapyIntensity-modulated radiation therapyProgression-free survivalOropharyngeal cancerPhase 3 trialPhoton radiotherapyOpen-labelSystemic therapyProton therapyNon-inferiority phase 3 trialStandard-of-care treatment optionEastern Cooperative Oncology Group performance statusInstitutional multidisciplinary tumour boardProgression-free survival ratesIntention-to-treat populationSurvival rateConcurrent systemic therapyDe-intensify treatmentDisease control rateIV oropharyngeal cancerTreatment-related deathsTreated with radiotherapyMD Anderson Cancer CenterInternational guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers
Biau J, Nutting C, Langendijk J, Thariat J, O’Sullivan B, Cacicedo J, Blanchard P, Lee N, McBride S, Caudell J, Rosenthal D, Yom S, McDowell L, Chua M, Bourhis J, Grégoire V, Lapeyre M. International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers. Radiotherapy And Oncology 2025, 214: 111317. PMID: 41317999, DOI: 10.1016/j.radonc.2025.111317.Commentaries, Editorials and LettersConceptsClinical target volumeSubmandibular gland cancerPost-operative radiotherapyPerineural invasionTarget volumeClinical target volume delineationNodal clinical target volumePostoperative clinical target volumeNatural historyPatient-specific risk factorsEra of IMRTLocal tumor spreadSalivary gland cancerImaging-pathology correlationConsensus-based guidelinesCTV delineationTumor extensionRadiation oncologistsTumor spreadCTV-pConsensus guidelinesConformal techniquePrimary siteConsensus statementRisk factorsPatient-reported outcomes after ipsilateral radiation therapy for N2b tonsillar squamous cell carcinoma
Abana C, Garden A, Brandon Gunn G, Chronowski G, Mohamed A, Frankart A, Geier N, Bahig H, Barbon C, Hutcheson K, Takiar V, Fuller C, Frank S, Rosenthal D, Phan J. Patient-reported outcomes after ipsilateral radiation therapy for N2b tonsillar squamous cell carcinoma. Discover Oncology 2025, 16: 2165. PMID: 41288848, PMCID: PMC12647442, DOI: 10.1007/s12672-025-03896-z.Peer-Reviewed Original ResearchSquamous cell carcinomaTonsillar squamous cell carcinomaPatient-reported outcomesRadiation therapyHead and neckCell carcinomaDry mouthTreatment volumeHuman papillomavirus-positive diseaseHead and neck symptomsTonsil squamous cell carcinomaPatient-reported outcomes of patientsHead and neck cancerPhysician-assessed toxicityResultsForty-eight patientsAssociated with lower ratesAJCC-7N2b diseaseNeck RTExtranodal extensionSystemic therapyCore symptomsNeck cancerGeneral activityInterference symptomsPerspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries
Murphy-Alford A, Grossberg A, Baracos V, Barbar M, Bauer J, Bennett J, Fidarova E, Fuller C, Löser A, Moreno A, Patra A, Puttaswamy D, Rosenthal D, Schoeman J, Anacak Y. Perspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries. Advances In Nutrition 2025, 17: 100563. PMID: 41242549, PMCID: PMC12756699, DOI: 10.1016/j.advnut.2025.100563.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPatient's nutritional statusMiddle-income countriesRates of co-morbiditiesAdverse clinical outcomesRadiotherapy patientsTreatment toleranceDelayed DiagnosisClinical outcomesVulnerability of cancer patientsCancer patientsCo-morbiditiesMuscle lossNutritional careBody compositionNutritional statusCancer treatmentPatientsRadiotherapyHigh-income countriesHeightened vulnerabilityEvidence gapsUnmet needsTreatmentOutcomesMiddle-incomeDesigning an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Moreno A, Peek A, Stein T, Shook K, Ali S, Humbert-Vidan L, Chen A, Lango M, Lee A, Spiotto M, Morrison W, Garden A, Phan J, Frank S, Hutcheson K, Rosenthal D, Fuller C, Gunn G. Designing an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework. Advances In Cancer Education And Quality Improvement 2025, 1: 6. PMID: 41624751, PMCID: PMC12854710, DOI: 10.52519/aceqi.25.1.2.a6.Peer-Reviewed Original ResearchPatient-reported outcomesRE-AIMElectronic PROsImplementation of electronic patient-reported outcomesRE-AIM implementation frameworkReach-Effectiveness-Adoption-Implementation-MaintenanceElectronic patient-reported outcomesRE-AIM metricsElectronic health recordsInformation infrastructureHead and Neck ModuleQuality of lifeEPRO dataEHR systemsHealth recordsClinical staffOncology clinicImplementation evaluationProgram facilitatorsRadiation oncology clinicInformation toolsEHR platformCompliance rateMDASI-HNNeck ModuleLong-Term Feeding Tube Use in Head and Neck Cancer Survivors—An Analysis of Patient- and Treatment-Related Factors
Galloway T, Pugh S, Ridge J, Nguyen-Tan P, Rosenthal D, Gillison M, Garden A, Dunlap N, Caudell J, Jones C, Bauman J, Bahig H, Shenouda G, Currey A, Koyfman S, Stokes W, Read N, Lyness J, Yom S, Le Q. Long-Term Feeding Tube Use in Head and Neck Cancer Survivors—An Analysis of Patient- and Treatment-Related Factors. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: 703-712. PMID: 40473230, PMCID: PMC12396613, DOI: 10.1016/j.ijrobp.2025.05.064.Peer-Reviewed Original ResearchIntensity modulated radiation therapyOropharynx cancer patientsOropharynx cancerFeeding tube useTube useAccelerated fractionationTreatment initiationPredictive factorsFeeding tubeIntensity modulated radiation therapy techniquesTreated with 3DCRTSecondary analysis of patientsT4 tumor stageAnalysis of patientsTreatment related factorsPost hoc secondary analysisTreatment completionYears of smokingSecondary analysisChemoradiation trialsConcurrent chemotherapyMedian followupConcomitant boostConformal radiationRadiation therapyMachine learning predicting acute pain and opioid dose in radiation treated oropharyngeal cancer patients
Salama V, Humbert-Vidan L, Godinich B, Wahid K, ElHabashy D, Naser M, He R, Mohamed A, Sahli A, Hutcheson K, Gunn G, Rosenthal D, Fuller C, Moreno A. Machine learning predicting acute pain and opioid dose in radiation treated oropharyngeal cancer patients. Frontiers In Pain Research 2025, 6: 1567632. PMID: 40256643, PMCID: PMC12006146, DOI: 10.3389/fpain.2025.1567632.Peer-Reviewed Original ResearchMorphine equivalent daily doseBaseline pain scoresPain intensityOpioid doseRadiation therapyAnalgesic efficacyPain scoresAcute painPatients treated with RTOral cavity/oropharyngeal cancerPersonalized pain managementPredicting pain intensityOropharyngeal cancer patientsAcute pain severityEquivalent daily doseEarly risk stratificationVital signsLogistic regressionRisk stratification modelOpioid requirementsPain severityDaily doseRetrospective studyRisk stratificationPain managementEvaluating observer reliability and diagnostic accuracy of CT-LEFAT criteria for post-treatment head and neck lymphedema: A prospective blinded comparative analysis
West N, Attia S, Kaffey Z, Dede C, Mulder S, El-Habashy D, Neuberger R, Naser M, Frank S, Mao S, McMillan H, Smith B, Rosenthal D, Lai S, Hutcheson K, Moreno A, Fuller C, Group A. Evaluating observer reliability and diagnostic accuracy of CT-LEFAT criteria for post-treatment head and neck lymphedema: A prospective blinded comparative analysis. Oral Oncology 2025, 164: 107265. PMID: 40174310, PMCID: PMC12087970, DOI: 10.1016/j.oraloncology.2025.107265.Peer-Reviewed Original ResearchConceptsHead and neck cancerArea under the curveDiagnostic accuracyRadiation therapyFat strandingHead-and-neck cancer patients treated with RTPatients treated with RTContrast-enhanced CT scanHead and neck lymphedemaIntra-observer agreementEvaluate diagnostic accuracyROC-AUC analysisNeck lymphedemaNeck cancerInter-observer reliabilityIntra-rater reliabilityCT scanFleiss’ kappa analysisDiagnostic performanceInter-rater reliabilityIntra-observerAUC analysisKappa analysisLymphedemaPhysician raters
Academic Achievements & Community Involvement
Clinical Care
Overview
David Rosenthal, MD, is a primary care physician who specializes in general internal medicine. He focuses on providing comprehensive health care services, especially to populations such as veterans experiencing homelessness.
As an associate professor at Yale School of Medicine, Dr. Rosenthal’s research interests include health care services for vulnerable populations and health informatics, aiming to improve accessibility and efficacy of care for all. He has developed and implemented innovative technology solutions to enhance patient care, including mobile apps for substance use disorder management.
Dr. Rosenthal received his medical training from Northwestern University Feinberg School of Medicine, followed by an internship and primary care residency at Brigham and Women's Hospital. He has been recognized by the Aspen Institute as a Health Innovator Fellow for his contributions to public health and innovation.
Clinical Specialties
News & Links
News
- February 26, 2026
Yale School of Medicine Auction Raises Over $20,000 to Fight Food and Housing Insecurity in New Haven
- June 11, 2025
Yale Internal Medicine Faculty and Trainees Receive Outstanding Teaching Awards
- March 11, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (March 2025)
- January 15, 2025
Student Auction Supports New Haven Nonprofits
Get In Touch
Contacts
General Internal Medicine
150 Sargent Dr
New Haven, CT 06511
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.